FDA Safety Decisions On Ketek To Get Formal Review By House Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Carefully worded request from the Energy and Commerce Committee seems designed to avoid pitfalls that Sen. Grassley’s investigation suffered.
You may also be interested in...
Non-Inferiority Studies May (Bio)Creep Out Of Limelight After GAO Report
A report on FDA's use of non-inferiority trials by the Government Accountability Office could in fact signal the end of the political wrangling over the study method
Non-Inferiority Studies May (Bio)Creep Out Of Limelight After GAO Report
A report on FDA's use of non-inferiority trials by the Government Accountability Office could in fact signal the end of the political wrangling over the study method
Theravance’s Telavancin Data Integrity Issues Resolved; FDA Review Back On Track
FDA will resume the review of Theravance’s antibiotic telavancin at a three-day advisory committee meeting in November after completing an audit of the company’s clinical trial data.